viernes, 30 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· October 22, 2026

Pierre & Vacances-Center Parcs Group: Full-Year 2025/2026 Revenue of €2 Billion, up 2.7% Including Growth of 5.5% for the Tourism Businesses

View original at finance.yahoo.com

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Group ended FY2025/2026 with a further increase in revenue, achieved in a challenging environment, showing the solidity of its business model and complementarity of its brands.

    60% confidence

  • The Group expects adjusted EBITDA of around €185 million for FY2025/2026, in line with guidance and up on FY2024/2025.

    60% confidence

  • Tourism reservations booked to date for Q1 2026/2027 are higher than the previous year across all Group brands.

    60% confidence

  • He welcomes Mubadala Capital taking over from current shareholders to support the next phase of growth, subject to completion.

    60% confidence

  • Operational execution quality is reflected in improved customer satisfaction.

    60% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,994
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,994 hechos verificados con la fuente5,514 documentos fuente archivados
Consulta estos datos → isubstrate.com